Active substance
Alcaftadine
- US FDA 4
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LASTACAFT | 0.25% | solution/drops · ophthalmic | ABBVIE | Over-the-counter | 28 Jul 2010 |
| ALCAFTADINE | 0.25% | solution/drops · ophthalmic | GLAND | Over-the-counter | 1 Mar 2024 |
| ALCAFTADINE | 0.25% | solution/drops · ophthalmic | ALEMBIC | Over-the-counter | 2 Oct 2024 |
| ALCAFTADINE | 0.25% | solution/drops · ophthalmic | EUGIA PHARMA | Discontinued | 23 Jun 2023 |
Safety signals and safety-related labeling changes
- US FDA 9 Jun 2020 LASTACAFT — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.